Search - tctmd.com

Displaying 1 - 20 of 51

Sort: Relevancy | Date

News Daily News

FDA Approves Lerodalcibep for Adults With Hypercholesterolemia

Yael L. Maxwell

December 15, 2025

News Daily News

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Michael O'Riordan

May 07, 2025

News Daily News

Topline Data Point to Promise for VERVE-102 Gene-Editing Therapy

Caitlin E. Cox

April 14, 2025

News Daily News

Top General Cardiology and Prevention News of 2024

Caitlin E. Cox

December 30, 2024

News Daily News

Marked LDL Lowering With Obicetrapib in HeFH: BROOKLYN

Michael O'Riordan

July 29, 2024

News Daily News

Diagnosing FH in Kids and Teens Should Happen Early: In Real Life, It Varies

Michael O'Riordan

December 19, 2023

News Daily News

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Michael O'Riordan

December 06, 2023

News Daily News

Mortality Risk Varies Among Patients With Very High LDL Levels

Michael O'Riordan

November 17, 2023

News Daily News

USPSTF: Screening Kids for Lipid Disorders Still Needs More Data

Shelley Wood

July 18, 2023

News Daily News

Don’t Just Prescribe a Statin—Measure and Control LDL, Say NLA, ASPC

Michael O'Riordan

March 01, 2023

News Daily News

Zero CAC? LDL Cholesterol May Not Predict MI, ASCVD

Yael L. Maxwell

January 17, 2023

News Daily News

How Lp(a) Levels Compare With LDL-C in FH: Some Surprises

Michael O'Riordan

November 17, 2022

News Daily News

High Lp(a) May Predict Risk of CV and Limb Events in PAD

L.A. McKeown

July 18, 2022

News Daily News

New CAC Risk Tool Helps Contextualize Scores for Younger Adults

Yael L. Maxwell

May 12, 2022

News Daily News

Homozygous FH Diagnosis Often Comes Late, With Lackluster Care

Michael O'Riordan

February 10, 2022

News Daily News

Statins in Pregnancy Don’t Lead to Congenital Anomalies: Cohort Study

Yael L. Maxwell

January 03, 2022

News Daily News

FDA Approves Inclisiran, a Twice-Yearly Injection to Lower LDL Levels

Michael O'Riordan

December 22, 2021

News Daily News

British Medical Groups Express Concern About Inclisiran Rollout

Michael O'Riordan

December 14, 2021

News Daily News

Cumulative Burden of LDL Cholesterol Increases CHD Risk

Michael O'Riordan

September 23, 2021

News Daily News

Heterozygous FH Diagnosed Late, Remains Undertreated

Michael O'Riordan

September 13, 2021

Advertisement

FDA Approves Lerodalcibep for Adults With Hypercholesterolemia

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Topline Data Point to Promise for VERVE-102 Gene-Editing Therapy

Top General Cardiology and Prevention News of 2024

Marked LDL Lowering With Obicetrapib in HeFH: BROOKLYN

Diagnosing FH in Kids and Teens Should Happen Early: In Real Life, It Varies

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Mortality Risk Varies Among Patients With Very High LDL Levels

USPSTF: Screening Kids for Lipid Disorders Still Needs More Data

Don’t Just Prescribe a Statin—Measure and Control LDL, Say NLA, ASPC

Zero CAC? LDL Cholesterol May Not Predict MI, ASCVD

How Lp(a) Levels Compare With LDL-C in FH: Some Surprises

High Lp(a) May Predict Risk of CV and Limb Events in PAD

New CAC Risk Tool Helps Contextualize Scores for Younger Adults

Homozygous FH Diagnosis Often Comes Late, With Lackluster Care

Statins in Pregnancy Don’t Lead to Congenital Anomalies: Cohort Study

FDA Approves Inclisiran, a Twice-Yearly Injection to Lower LDL Levels

British Medical Groups Express Concern About Inclisiran Rollout

Cumulative Burden of LDL Cholesterol Increases CHD Risk

Heterozygous FH Diagnosed Late, Remains Undertreated

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content